Y 101 D
Alternative Names: Y-101-DLatest Information Update: 26 Feb 2024
At a glance
- Originator YZY Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Programmed cell death-1 ligand-1 modulators; TGF-beta superfamily protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Pancreatic cancer
- Phase I Solid tumours
Most Recent Events
- 08 Feb 2023 Phase-I/II clinical trials in Pancreatic cancer (In adults, In the elderly, Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in China (IV) (NCT06266143)
- 06 Aug 2021 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in China (IV) (NCT05028556) .